RE:RE:RE:RE:RE:RE:RE:RE:POTENTIAL HOME CANCER TREATMENT
Rutherrin & TLD 1433 are practically twins from a biological safety profile imo. Keep in mind, Ruthenium/TLD 1433 closely mimics its relative, iron. This enables it to have a high "affinity for transferrin" (a natural transporter of iron in the body), which is one of the core reasons for its low in vivo toxicity... as evidenced thus far in our current NMIBC study.
Based on the composition of Rutherrin (TLD 1433 + transferrin), I see no concerns with safety at the doses likely required. Futhermore, it's very plausible to conclude that modifying the core of our compound (i.e. changing the ligand) or using a similar metal of the same group (i.e. Osmium, etc.) will "not" significantly change the safety profile, which again is excellent thus far for this family of elements. JMO.